Cargando…
Pharmacogenomics of Human Drug Transporters : Clinical Impacts.
Highlighting the internationally hot topic of pharmacogenomics and its influence on drug therapy, Pharmacogenomics of Human Drug Transporters reviews individual drug transporters, including specific transporter families and clinical implications. This book serves as a comprehensive guide to drug tra...
| Clasificación: | Libro Electrónico |
|---|---|
| Autor principal: | |
| Otros Autores: | , |
| Formato: | Electrónico eBook |
| Idioma: | Inglés |
| Publicado: |
Chicester :
Wiley,
2013.
|
| Temas: | |
| Acceso en línea: | Texto completo |
Tabla de Contenidos:
- Pharmacogenomics of human drug transporters; contents; preface; contributors; chapter 1 introduction to pharmacogenomics of drug transporters; 1.1 introduction; 1.2 overview of drug transporters; 1.3 overview of pharmacogenomics; 1.4 pharmacogenomics of drug transporters; 1.5 techniques to study drug transporter function; 1.6 transporter pharmacogenomics in drug discovery and development; 1.7 clinical implications of transporter pharmacogenomics; 1.8 conclusion; acknowledgments; references; chapter 2 adme pharmacogenomics in drug development; 2.1 introduction.
- 2.2 CURRENT ADME PHARMACOGENOMIC PRACTICES IN DRUG DEVELOPMENT AND CLINICAL PRACTICES2.2.1 Pharmacogenomic Study Conduct in Drug Development; 2.2.2 Regulatory Perspective and Available PGx Tests in Clinical Practices; 2.3 CURRENT PHARMACOGENOMICS APPROACHES AND METHODOLOGIES; 2.3.1 Candidate Gene Approach; 2.3.2 Genome-wide Association Studies; 2.3.3 Pathway-Based Approach; 2.4 RECENT ADVANCES IN PHARMACOGENOMICS OF MEMBRANE TRANSPORTERS; 2.4.1 Effect on Drug Level; 2.4.2 Association with Drug-induced Toxicity; 2.4.3 Impact on Drug Efficacy; 2.4.4 Underlining Disease Mechanism.
- 2.5 ADME PHARMACOGENOMICS: CHALLENGES AND OPPORTUNITIES2.5.1 Establish Genotype and Phenotype Correlations; 2.5.2 Improve Understanding Transporter Role in Drug Disposition; 2.5.3 Adopt a Holistic and Integrated Approach; 2.5.4 Educate Clinical Practitioners; 2.6 CONCLUSION; REFERENCES; CHAPTER 3 REGULATORY PERSPECTIVE ON PHARMACOGENOMICS OF DRUG-METABOLIZINGENZYMES AND TRANSPORTERS; 3.1 INTRODUCTION; 3.2 PHARMACOGENOMICS OF METABOLIZING ENZYMES; 3.2.1 CYP2C9 and Warfarin; 3.2.2 CYP2C19 and Clopidogrel; 3.2.3 CYP2D6 and Tetrabenazine; 3.3 PHARMACOGENOMICS OF TRANSPORTERS.
- 3.3.1 ABC Transporters3.3.2 SLC Transporters; 3.4 PHARMACOGENOMICS OF OTHER GENES; 3.4.1 Panitumumab (and Cetuximab) and KRAS; 3.4.2 Carbamazepine and HLA; 3.5 FDA CLINICAL PHARMACOGENOMIC GUIDANCE; 3.6 FUTURE PERSPECTIVES; REFERENCES; FDA WEB SITES; CHAPTER 4 THE PHARMACOGENOMICS OF MEMBRANE TRANSPORTERS PROJECT; 4.1 INTRODUCTION; 4.2 FUNCTIONAL GENOMIC STUDIES OF ABC AND SLC SUPERFAMILY TRANSPORTERS; 4.2.1 ABCB1 (MDR1/P-gp); 4.2.2 ABCC2 (MRP2); 4.2.3 ABCC4 (MRP4); 4.2.4 ABCB11 (BSEP); 4.2.5 SLC22A1, SLC22A2, SLC22A3 (OCT1, OCT2, OCT3); 4.2.6 SLC22A4 and SLC22A5 (OCTN1 and OCTN2).
- 4.2.7 SLC47A1 (MATE1)4.2.8 SLCO1A2 (OATP1A2); 4.2.9 SLC28A and SLC29A (CNT and ENT); 4.3 CLINICAL STUDIES; 4.3.1 Metformin; 4.3.2 Gabapentin; 4.3.3 Irinotecan; 4.4 FUTURE DIRECTIONS; ACKNOWLEDGMENTS; REFERENCES; CHAPTER 5 EMERGING NEW TECHNOLOGY OF SNP TYPING; 5.1 INTRODUCTION; 5.2 CURRENT TECHNOLOGIES OF SNP DETECTION; 5.2.1 Allele-specific Hybridization; 5.2.2 Enzymatic Cleavage; 5.2.3 Allele-specific PCR; 5.2.4 Mass-based Detection; 5.2.5 Fluorescent Method; 5.2.6 Invader Assay (Enzymatic Cleavage); 5.3 SmartAmp METHOD; 5.4 MOLECULAR MECHANISM UNDERLYING ISOTHERMAL DNA AMPLIFICATION.